Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain.
Analgesics
/ chemical synthesis
Animals
Anti-Inflammatory Agents
/ chemical synthesis
Cyclooxygenase 2
/ metabolism
Disease Models, Animal
Edema
/ metabolism
Hyperalgesia
/ metabolism
Locomotion
/ drug effects
Macrophages
/ drug effects
Male
Mice
Nitric Oxide
/ metabolism
Nociceptive Pain
/ metabolism
Pain Threshold
/ drug effects
Pyridones
/ chemical synthesis
RAW 264.7 Cells
Rats, Wistar
Receptor, Adenosine A1
/ metabolism
Signal Transduction
Adenosine A1 receptor
Edema
Formalin test
Oxaliplatin-induced model
Tactile allodynia
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
17
04
2019
accepted:
28
11
2019
pubmed:
21
12
2019
medline:
22
4
2021
entrez:
21
12
2019
Statut:
ppublish
Résumé
The aim of the presented study was to examine the potential antinociceptive, antiedematous (anti-inflammatory), and antiallodynic activities of two 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives (DSZ 1 and DSZ 3) in various experimental models of pain. For this purpose, the hot plate test, the capsaicin test, the formalin test, the carrageenan model, and oxaliplatin-induced allodynia tests were performed. In the hot plate test, only DSZ 1 in the highest dose (20 mg/kg) was active but its effects appear to be due to sedatation rather than antinociceptiveness. In capsaicin-induced neurogenic pain model, both compounds displayed a significant antinociceptive activity. In the formalin test, DSZ 1 and DSZ 3 (5-20 mg/kg) revealed antinociceptive activity in both phases but it was more pronounced in the second phase of the test. In this test, pretreatment with caffeine, DPCPX reversed the antinociceptive effect of DSZ 3. On the other hand, pretreatment with L-NAME diminished the antinociceptive effect of DSZ 1. Pretreatment with naloxone did not affect antinociceptive activity of both compounds. Similar to ketoprofen, DSZ 1 and DSZ 3 showed antiedematous (antiinflammatory) and antihyperalgesic activity, and similar to lidocaine local anesthetic activity. Furthermore, both compounds (5 and 10 mg/kg) reduced tactile allodynia in acute and chronic phases of neuropathic pain. In the in vitro studies, DSZ 1 and DSZ 3 reduced the COX-2 level in LPS-activated RAW 264.7 cells, which suggests their anti-inflammatory activity. In conclusion, both DSZ 1 and DSZ 3 displayed broad spectrum of activity in several pain models, including neurogenic, tonic, inflammatory, and chemotherapy-induced peripheral neuropathic pain.
Identifiants
pubmed: 31858155
doi: 10.1007/s00210-019-01783-3
pii: 10.1007/s00210-019-01783-3
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents
0
Pyridones
0
Receptor, Adenosine A1
0
Nitric Oxide
31C4KY9ESH
Ptgs2 protein, mouse
EC 1.14.99.-
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-827Références
Brain Res Rev. 2006 Aug;51(2):240-64
pubmed: 16388853
Nitric Oxide. 2011 Oct 30;25(3):243-54
pubmed: 21723953
Exp Brain Res. 2009 Jun;196(1):5-11
pubmed: 19294370
Eur J Pharmacol. 2005 Apr 18;513(1-2):81-91
pubmed: 15878712
Eur J Pharmacol. 2012 Jan 15;674(2-3):248-54
pubmed: 22085758
J Neurosci Methods. 1985 Jun;14(1):69-76
pubmed: 4033190
Neurosci Lett. 2008 Aug 1;440(2):181-4
pubmed: 18562097
Eur J Pharmacol. 2009 Mar 1;605(1-3):95-102
pubmed: 19168051
Neurosci Lett. 2010 Apr 12;473(3):178-81
pubmed: 20176083
Pharmacol Biochem Behav. 2015 Aug;135:13-9
pubmed: 25989045
Farmaco. 2005 Jan;60(1):53-9
pubmed: 15652370
Pharmazie. 2001 Feb;56(2):133-8
pubmed: 11234340
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13525-30
pubmed: 17686976
Biomed Pharmacother. 2019 Mar;111:882-890
pubmed: 30841467
Eur J Pain. 2014 Aug;18(7):939-48
pubmed: 24395183
Toxicol Lett. 2016 Sep 6;258:93-100
pubmed: 27329536
Molecules. 2016 Jun 28;21(7):
pubmed: 27367653
Eur J Pharmacol. 1991 Aug 16;201(1):121-2
pubmed: 1665419
J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
pubmed: 18152921
Eur J Pharmacol. 1995 Apr 13;277(1):21-8
pubmed: 7635169
Pharmacol Res. 2005 Mar;51(3):197-203
pubmed: 15661568
Br J Anaesth. 2017 Oct 1;119(4):737-749
pubmed: 29121279
Neuropharmacology. 2013 Feb;65:206-12
pubmed: 23098993
Acta Pol Pharm. 2006 Jul-Aug;63(4):245-54
pubmed: 17203859
Eur J Med Chem. 2018 Oct 5;158:517-533
pubmed: 30245393
Acta Pol Pharm. 2017 Mar;74(2):435-443
pubmed: 29624249
Pharmacol Biochem Behav. 2014 Jul;122:173-81
pubmed: 24726707
Arch Int Pharmacodyn Ther. 1957 Sep 1;111(4):409-19
pubmed: 13471093
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
pubmed: 14001233
Int J Biochem Cell Biol. 2006;38(10):1654-61
pubmed: 16713323
Farmaco. 2002 Nov;57(11):897-908
pubmed: 12484538
J Pharmacol Exp Ther. 1953 Mar;107(3):385-93
pubmed: 13035677
Eur J Pharmacol. 2001 Aug 24;426(1-2):39-44
pubmed: 11525769
J Zhejiang Univ Sci B. 2015 Mar;16(3):167-78
pubmed: 25743118
Pharmacol Rep. 2016 Dec;68(6):1285-1292
pubmed: 27689756
J Basic Clin Physiol Pharmacol. 1994 Apr-Jun;5(2):125-31
pubmed: 8736044
Free Radic Biol Med. 2011 Sep 1;51(5):951-66
pubmed: 21277369
Neuroscience. 2016 Dec 3;338:1-18
pubmed: 26500181
Nitric Oxide. 2015 May 1;47:17-24
pubmed: 25754796